- Home
- BYSI vs ADAG Comparison
BYSI vs ADAG Comparison
Compare BYSI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- ADAG
- Stock Information
- Founded
- BYSI 2010
- ADAG 2011
- Country
- BYSI United States
- ADAG China
- Employees
- BYSI N/A
- ADAG N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- ADAG Health Care
- Exchange
- BYSI Nasdaq
- ADAG Nasdaq
- Market Cap
- BYSI 99.5M
- ADAG 95.6M
- IPO Year
- BYSI 2017
- ADAG 2021
- Fundamental
- Price
- BYSI $1.62
- ADAG $2.14
- Analyst Decision
- BYSI
- ADAG Strong Buy
- Analyst Count
- BYSI 0
- ADAG 1
- Target Price
- BYSI N/A
- ADAG $5.00
- AVG Volume (30 Days)
- BYSI 25.5K
- ADAG 73.9K
- Earning Date
- BYSI 01-01-0001
- ADAG 07-25-2024
- Dividend Yield
- BYSI N/A
- ADAG N/A
- EPS Growth
- BYSI N/A
- ADAG N/A
- EPS
- BYSI N/A
- ADAG N/A
- Revenue
- BYSI $1,876,000.00
- ADAG $815,746.00
- Revenue This Year
- BYSI N/A
- ADAG N/A
- Revenue Next Year
- BYSI N/A
- ADAG $2.70
- P/E Ratio
- BYSI N/A
- ADAG N/A
- Revenue Growth
- BYSI 21.03
- ADAG N/A
- 52 Week Low
- BYSI $0.78
- ADAG $1.34
- 52 Week High
- BYSI $4.00
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- BYSI 24.99
- ADAG 37.47
- Support Level
- BYSI $1.85
- ADAG $2.20
- Resistance Level
- BYSI $2.10
- ADAG $3.14
- Average True Range (ATR)
- BYSI 0.17
- ADAG 0.30
- MACD
- BYSI -0.05
- ADAG -0.09
- Stochastic Oscillator
- BYSI 15.02
- ADAG 18.63
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.